Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 25,184 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Pre-diabetes, Diabetes
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Conditions: Healthy Volunteers From Racial/Ethnic Minority Populations
Interventions: EXPLORER PET/CT; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cardiac Toxicity, Lymphoma
Interventions: bleomycin sulfate, filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 36
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 28 more

Conditions: Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions: Miro3D Wound Matrix, Standard of Care (SOC); Device · Other
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Coconut Creek, Florida • Tamarac, Florida • New York, New York

Conditions: Heart Transplant, Small Intestine Transplant, Kidney Transplant, Liver Transplant, EBV-Related PTLD, PTLDs
Interventions: transplant, Immunosuppressive Drugs; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 4 more

Conditions: HER2-positive Early-stage Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Docetaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more

Conditions: Preeclampsia
Interventions: Aspirin; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Ovary Syndrome, Insulin Resistance
Interventions: Cinnamon Supplementation, Placebo (wheat flour); Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Stroke Prevention, Blood Pressure Reduction
Interventions: STEP Clinic, Usual Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Adults
Interventions: Follistatin and klotho gene therapy; Genetic
Lead sponsor: Minicircle; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ulcerative Colitis Acute
Interventions: Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior
Interventions: Oromotor stimulation, Reading curriculum, LENA recording, LENA linguistic feedback, No oromotor stimulation; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Clinical Sepsis
Interventions: Sepsis Transition And Recovery (STAR), Usual care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Endometrial Cancer
Interventions: Hypofractionated Radiation, Clinical Follow-Up and Assessments; Radiation · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more

Conditions: Breast Cancer
Interventions: No intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Suicidal Ideation, Suicide, Attempted, Nonsuicidal Self-injury
Interventions: Safety Planning, Standard care; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Small Cell Lung Cancer
Interventions: Alisertib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 30
States / cities: Daphne, Alabama • Long Beach, California • Lone Tree, Colorado + 24 more

Conditions: Suicidal Ideation, Deliberate Self-harm, Impulsivity
Interventions: Calm program; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 13 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Spinal Cord Injuries and Disorders (SCI/D), Spinal Cord Injury
Interventions: Motor Evoked Potential (MEP) Operant Conditioning; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostate Cancer
Interventions: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT; Drug
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Foot and Ankle Surgeries, Bunion
Interventions: Tranexamic Acid, Normal saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: Inhaled Cannabis, Oral THC, Oral Placebo, Inhaled placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Positive Psychology + Motivational Interviewing, Motivational Interviewing; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: LGX818; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Gender Differences in Prevalence of Undiagnosed Diabetes in ACS

EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

Predictors of Aspirin Failure in Preeclampsia Prevention

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

STEPs to Blood Pressure Reduction.

Safety and Efficacy of Klotho and Follistatin Gene Therapy

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Combined Oral Motor Stimulation and Language on Preterm Infant Feeding

Improving Morbidity During Post-Acute Care Transitions for Sepsis

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)

Safety Planning in Juvenile Justice for Suicidal Youth

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

An Online Intervention to Reduce Self-Harm Among Persons With High Emotion-Related Impulsivity

Motoneuron Recruitment and Motor Evoked Potential Up-Conditioning (MEP) in Spinal Cord Injury (SCI)

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Efficacy of Tranexamic Acid in Foot and Ankle Surgeries

Cannabis for Spasticity in Multiple Sclerosis

Boosting Emotional Well-being and Happiness in Outpatients Living With Diabetes

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC